Touyun Biotech (01332) has signed a strategic cooperation agreement with Shenzhen University to jointly develop the Chlorella Growth Factor project.

TOUYUN BIOTECH (01332) announced that on April 15, 2026, its wholly-owned subsidiary Shanxi TOUYUN BIOTECH Technology Co., Ltd. has entered into a strategic cooperation agreement for the transformation of scientific achievements with Shenzhen University. According to the agreement, Shanxi Touyun and Shenzhen University will jointly establish the "Shenzhen University-TOUYUN BIOTECH Rhine Chlamydomonas Joint Research Institute", which is a research and development platform that is not an independent legal entity. The cooperation period is five years, with the option to automatically renew upon expiration. The joint research institute will focus on establishing a genetic resource preservation center for Rhine Chlamydomonas in China, a synthetic biology toolbox, a pilot plant, and a talent training and academic exchange center. Shanxi Touyun will provide a total of 5 million RMB in cooperation funds to Shenzhen University, to be paid over five years at a rate of 1 million RMB per year, for research and operational expenses of the joint research institute. The first batch of projects to be launched is the "Chlamyglutide Project", based on Shenzhen University's patent achievement "A Stable Expression Human GLP-1RA Chlamydomonas Engineered Strain and Construction Method and Application (CN2025115510147)", which is currently undergoing pilot development, biopharmaceutical product licensing approval, and industrial applications at Shanxi Touyun. According to the agreement, Shenzhen University (including the inventors' team) will receive a certain percentage of future revenue from the Chlamyglutide project product sales. Shanxi Touyun will be responsible for pilot testing, production licensing, clinical usage approval, and scale-up production and sales. Shenzhen University will provide the necessary technical documents for compliance approval, engineering strains, and product application instructions, as well as provide professional training for Shanxi Touyun production and technical staff. Shanxi Touyun and Shenzhen University will enter into separate agreements on intellectual property rights, algal strain management, and confidentiality responsibilities to ensure that the cooperation results are properly protected. Shenzhen University is a comprehensive university founded in 1983. Since establishing the Rhine Chlamydomonas synthetic biology research group in 1999, it has published over 400 related research papers, ranking at the forefront nationwide, and has successfully built China's first medicinal single-celled eukaryotic micro-algae engineered strain library. Shenzhen University has successfully developed the patented achievement Chlamyglutide based on the Rhine Chlamydomonas model platform. Entering into this agreement with Shenzhen University will provide the group with an exclusive opportunity to collaborate with a world-leading patent and top synthetic biology team, ensuring the continuous introduction of high-value new products such as the Chlamyglutide project. The agreement also ensures that the group has priority or exclusive rights to commercialize the relevant technologies, preventing competitors from acquiring key intellectual property rights. Combining Shenzhen University's research strength with Shanxi Touyun's existing production facilities and global patents, a seamless and rapid pathway will be established from research to mass production and sales.